We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Raysearch Laboratories AB (RAY B) SER 'B' NPV

Sell:138.80 SEK Buy:139.60 SEK Change: 3.40 SEK (2.50%)
Market closed |  Prices as at close on 12 July 2024 | Switch to live prices |
Sell:138.80 SEK
Buy:139.60 SEK
Change: 3.40 SEK (2.50%)
Market closed |  Prices as at close on 12 July 2024 | Switch to live prices |
Sell:138.80 SEK
Buy:139.60 SEK
Change: 3.40 SEK (2.50%)
Market closed |  Prices as at close on 12 July 2024 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

RaySearch Laboratories publ AB is a Sweden-based medical technology company that develops software for radiation therapy of cancer. It markets and sells its products mainly in the United States and in Europe through license agreements with medical technology companies and scientific institutions. As of December 31, 2011, 15 of the Company’s products were launched, including the software platform ORBIT (optimization of radiation therapy beams by iterative technique), which is available in its main products, and is a non-clinical system which functions as a research and development environment. Additionally, its solutions include software for optimizing Intensity Modulated Radiation Therapy (IMRT) plans for photons, adaptive technology for IMRT treatments and software for proton treatments. The Company’s commercial partners are Philips, Nucletron and IBA Dosimetry, among others. In April 2014, it established a German subsidiary, RaySearch Germany GmbH.

Contact details

Eugeniavagen 18C
104 30
+46 (8) 51053000

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
3.62 billion SEK
Shares in issue:
34.28 million
Health Care Technology
Stockholm Stock Exchange
Swedish Krona

Key personnel

  • Johan Loef
    Chief Executive Officer, Founder, Director
  • Bjoern Hardemark
    Deputy Chief Executive Officer
  • Annika Henriksson
    Chief Financial Officer
  • Kjell Eriksson
    Chief Science Officer
  • Petra Jansson
    General Counsel
  • Lars Jordeby
    Director of Sales and Marketing, Asia-Pacific and Middle East
  • Peter Kemlin
    Director of Sales and Marketing
  • Tove Altebor
    Global Human Resource Manager
  • Niclas Borglund
    Director of Service
  • Henrik Friberger
    Director of Development

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.